Dżaman Karolina, Czerwaty Katarzyna
Department of Otolaryngology, Centre of Postgraduate Medical Education, Marymoncka 99/103, 01-813 Warsaw, Poland.
Pharmaceutics. 2023 Apr 24;15(5):1327. doi: 10.3390/pharmaceutics15051327.
It is estimated that there are over 890,000 new cases of head and neck squamous cell carcinoma (HNSCC) worldwide each year, accounting for approximately 5% of all cancer cases. Current treatment options for HNSCC often cause significant side effects and functional impairments, thus there is a challenge to discover more acceptable treatment technologies. Extracellular vesicles (EVs) can be utilized for HNSCC treatment in several ways, for example, for drug delivery, immune modulation, as biomarkers for diagnostics, gene therapy, or tumor microenvironment modulation. This systematic review summarizes new knowledge regarding these options. Articles published up to 11 December 2022, were identified by searching the electronic databases PubMed/MEDLINE, Scopus, Web of Science, and Cochrane. Only full-text original research papers written in English were considered eligible for analysis. The quality of studies was assessed using the Office of Health Assessment and Translation (OHAT) Risk of Bias Rating Tool for Human and Animal Studies, modified for the needs of this review. Of 436 identified records, 18 were eligible and included. It is important to note that the use of EVs as a treatment for HNSCC is still in the early stages of research, so we summarized information on challenges such as EV isolation, purification, and standardization of EV-based therapies in HNSCC.
据估计，全球每年有超过89万例头颈部鳞状细胞癌（HNSCC）新发病例，约占所有癌症病例的5%。HNSCC目前的治疗方案往往会导致显著的副作用和功能障碍，因此，发现更可接受的治疗技术是一项挑战。细胞外囊泡（EVs）可通过多种方式用于HNSCC治疗，例如，用于药物递送、免疫调节、作为诊断生物标志物、基因治疗或肿瘤微环境调节。本系统综述总结了关于这些选择的新知识。通过检索电子数据库PubMed/MEDLINE、Scopus、Web of Science和Cochrane，确定了截至2022年12月11日发表的文章。仅英文撰写的全文原创研究论文被认为有资格进行分析。使用健康评估与翻译办公室（OHAT）针对人类和动物研究的偏倚风险评级工具对研究质量进行评估，并根据本综述的需要进行了修改。在436条已识别的记录中，18条符合条件并被纳入。需要注意的是，将EVs用作HNSCC的治疗方法仍处于研究初期，因此我们总结了有关HNSCC中EV分离、纯化和基于EV的治疗标准化等挑战的信息。
